What Stance Do I Have on KCentra vs Andexxa for DOAC Reversal? - #QLAB

I'd love to answer your questions on the Q-LAB! I'll be posting them here in case others have a similar question. Here are my thoughts -

---

Where are you at on sICH + doac reversal? Kcentra or andexxa? I felt pretty strongly about this but find myself wavering a bit… - @neurodan23

Where do I currently stand on Andexxa vs KCentra for DOAC reversal.

AA over 4F-PCC for DOAC reversal (apixaban and rivaraxaban). Results from a retrospective trial including 4500 patients associated AA with reduced in-hospital mortality (50%?!) were presented at the 2023 International Society of Thrombosis and Haemestasis Conference (still pending official release). ANEXXA-I stopped early for positive results. There isn't a huge cost difference anymore. Definitely 4F-PCC for surgical patients given the ANEXXA-S trial. Terminated early, 7/10 patients with severe adverse events. That's the problem with single arm trials. 🤷🏻‍♂️

CC: @NATFthrombosis (X, formerly Twitter)

Thanks for the question!

Mark Nguyen, PharmD, BCEMP

---

If you'd like to submit a question related to pharmacy residency (PGY1/PGY2), pharmacy school, emergency medicine, critical care, pharmaceuticals or anything #PHARMWYZE, CLICK HERE and I'll share it for others to see, or shoot me a DM on Instagram, Facebook, TikTok, Youtube, X, Threads, or LinkedIn.